MetaCap

Processa Pharmaceuticals Inc. (PCSA)

NASDAQ: PCSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.56-0.13 (-7.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PCSA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$68.29
52-week range
1.04 – 8.88
Day range
1.39 – 1.66
Volume / Avg
69.95K / 79.50K
Beta
—

52-week range

$1.04$8.88

PCSA stock today

Processa Pharmaceuticals (PCSA) closed at $1.56 on Nov 20, down 7.69% (-$0.13), versus the S&P 500's 3.70% decline. Shares are 82.4% below their 52-week high of $8.88 and 49.9% above the 52-week low of $1.04, near the bottom of the past year's range. Processa Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$68.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Processa Pharmaceuticals

Company profile

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. George K. Ng Esq., J.D.
Headquarters
Vero Beach, FL
Employees
12

Financial highlights

Full financials

Processa Pharmaceuticals reported a net loss of $13.6 million, compared with a loss of $11.9 million a year earlier. Diluted earnings per share came in at -$10.36.

Processa Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$0$0
Growth—————
Net income$-13.56M$-11.85M$-11.12M$-27.42M$-11.43M
EPS (diluted)$-10.36$-96.78$-8.48$-34.05$-0.75

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-61.58 vs —

PCSA news

All PCSA news

Processa Pharmaceuticals peers

Health Care sector
PCSA peer companies
CompanyPrice% ChgMarket capCompare
CANFCan-Fite Biopharma Ltd ADR1.44-2.34%$4.35Mvs PCSA
PULMPulmatrix Inc.1.27-10.56%$4.64Mvs PCSA
SCNXScienture Holdings Inc.2.28-6.45%$4.07Mvs PCSA
BLRXBioLineRx Ltd. ADR0.9639-8.20%$4.80Mvs PCSA
LTRNLantern Pharma Inc.0.245-13.73%$3.89Mvs PCSA
ALZNAlzamend Neuro Inc.0.7758-23.94%$3.74Mvs PCSA
SILOSilo Pharma Inc.1.71-9.04%$3.69Mvs PCSA
BGMSBio Green Med Solution Inc.0.553-9.48%$3.66Mvs PCSA

Indexes, lists and sector

Processa Pharmaceuticals stock FAQ

What is Processa Pharmaceuticals's stock price today?

PCSA last traded at $1.56 as of Nov 20, 4:00 PM EST, down 7.69% on the day. Prices are delayed at least 15 minutes.

Who is Processa Pharmaceuticals's CEO?

Mr. George K. Ng Esq., J.D. is the chief executive officer of Processa Pharmaceuticals Inc., which has about 12 employees.

What is the PCSA 52-week high?

The 52-week high for PCSA is $8.88 and the 52-week low is $1.04. The stock is currently 82.4% below its high.

Compare PCSA